Erratum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair (Carcinogenesis (2012) 33(10) (1843-1853) DOI: 10.1093/carcin/bgs167);FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1843-1853

  Park, Yun Yong ^a   Jung, Sung Yun ^b   Jennings, Nicholas B ^a   Rodriguez Aguayo, Cristian ^a   Peng, Guang ^a   Lee, Se Ran ^c   Kim, Sang Bae ^a   Kim, Kyounghyun ^d   Leem, Sun Hee ^c   Lin, Shiaw Yih ^a   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a   Lee, Ju Seog ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Dong A University   (South Korea)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 84867310027     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgz062     Document Type: Erratum

References (39)

1. Levine, M. et al. (2003) Transcription regulation and animal diversity. Nature, 424, 147-151.
2. Darnell, J.E. Jr (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer, 2, 740-749.
3. Vogt, P.K. (2001) Jun, the oncoprotein. Oncogene, 20, 2365-2377.
4. Quinn, D.I. et al. (2005) Molecular markers of prostate cancer outcome. Eur. J. Cancer, 41, 858-887.
5. Brooks, T.A. et al. (2009) The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat. Rev. Cancer, 9, 849-861.
6. Yu, H. et al. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 9, 798-809.
7. Bild, A.H. et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439, 353-357.
8. Nakanishi, C. et al. (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer, 5, 297-309.
9. van de Vijver, M.J. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347, 1999-2009.
10. Oh, D.S. et al. (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol., 24, 1656-1664.
11. Li, J. et al. (2005) SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia, 7, 312-323.
12. Wang, I.C. et al. (2005) Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell Biol., 25, 10875-10894.
13. Gravel, S. et al. (2008) DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev., 22, 2767-2772.
14. Rodriguez, R. et al. (2008) Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell Death Differ., 15, 889-898.
15. Arai, M. et al. (2009) The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Liver Int., 29, 55-62.
16. Cizmecioglu, O. et al. (2008) Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle, 7, 3548-3555.
17. Pierce, A.J. et al. (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev., 13, 2633-2638.
18. Peng, G. et al. (2009) BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat. Cell Biol., 11, 865-872.
19. Ong, S.E. et al. (2006) A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc., 1, 2650-2660.
20. Simon, R. et al. (2007) Analysis of gene expression data using BRB-Array-Tools. Cancer Inform., 3, 11-17.
21. Thaker, P.H. et al. (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med., 12, 939-944.
22. Badve, S. et al. (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J. Clin. Pathol., 62, 6-12.
23. Fan, C. et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med., 355, 560-569.
24. Nitiss, J.L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 9, 338-350.
25. Gullotta, F. et al. (2010) Targeting the DNA double strand breaks repair for cancer therapy. Curr. Med. Chem.
26. Helleday, T. (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis, 31, 955-960.
27. Mi, J. et al. (2008) RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther., 16, 66-73.
28. Kalinichenko, V.V. et al. (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev., 18, 830-850.
29. Myatt, S.S. et al. (2008) Targeting FOXM1. Nat. Rev. Cancer, 8, 242.
30. Costa, R.H. (2005) FoxM1 dances with mitosis. Nat. Cell Biol., 7, 108-110.
31. Rakha, E.A. et al. (2009) Triple-negative/basal-like breast cancer: review. Pathology, 41, 40-47.
32. Dawson, S.J. et al. (2009) Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer, 45 (suppl. 1), 27-40.
33. Carey, L. et al. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol., 7, 683-692.
34. Carr, J.R. et al. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res., 70, 5054-5063.
35. Kwok, J.M. et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res., 8, 24-34.
36. Tan, Y. et al. (2007) Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell Biol., 27, 1007-1016.
37. Smith, L.A. et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337.
38. Bandyopadhyay, A. et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One, 5, e10365.
39. Gartel, A.L. A new target for proteasome inhibitors: FoxM1. Expert Opin. Investig. Drugs, 19, 235-242.